Condition

Adjuvant Therapy

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 15 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15
Recruiting7
Common interventions19
Lead sponsors shown12
Advertisement

Clinical trials

15 shown
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.NCT07622836 · 2026-06-05
RECRUITING
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:NCT07180693 · 2025-09-29
RECRUITING
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)NCT07019363 · 2025-06-15
RECRUITING
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan StudyNCT06719206 · 2025-03-01
RECRUITING
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLCNCT07748325 · 2025-01-10
RECRUITING
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsNCT06041776 · 2023-03-28
RECRUITING
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerNCT05292742 · 2021-07-02
RECRUITING
Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNCT07826052 · 2026-09-15
NOT_YET_RECRUITING
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.NCT07686185 · 2026-09-01
NOT_YET_RECRUITING
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNCT07101159 · 2025-09-01
NOT_YET_RECRUITING
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNCT07005557 · 2025-06-15
NOT_YET_RECRUITING
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)NCT06621459 · 2024-09-26
UNKNOWN
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With NeratinibNCT05599334 · 2022-07-05
COMPLETED
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast CancerNCT05189067 · 2022-01-31
UNKNOWN
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerNCT05186506 · 2022-01-01
NOT_YET_RECRUITING

Common interventions

CDK4/6 InhibitorDRUG2ChemotherapyDRUG2Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)DRUG2Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapyDRUG1Befotertinib + Icotinib placeboDRUG1DalpiciclibDRUG1Digital self-management programBEHAVIORAL1DocetaxelDRUG1Endocrine therapyDRUG1Endocrine Therapy (Optional)DRUG1EnsatinibDRUG1Icotinib + Befotertinib placeboDRUG1PaclitaxelDRUG1Pyrotinib+Trastuzumab+CapecitabineDRUG1SintilimabDRUG1Standard endocrine therapy combined with CDK4/6 InhibitorDRUG1Third-generation EGFR-TKIDRUG1TrastuzumabDRUG1Trastuzumab+Pertuzumab/TrastuzumabDRUG1

Trial status mix

RECRUITING7
NOT_YET_RECRUITING5
UNKNOWN2
COMPLETED1

Phase mix

PHASE26
PHASE34
NA2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.